In the phase 2 telemedicine trial, pemigatinib is going to be assessed in FGFR-altered pancreatic cancer, where the primary cohort includes patients with FGFR2 fusions and the secondary cohort includes patients with other known activating mutations in FGFR. The primary objective is ORR and is expected to reach ≥33% and <10% as an unfavorable response [82]. The gene discussed is FGFR2; the disease is pancreatic neoplasm.